Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
Eytan M. Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L. Liesveld, et al.. Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR alpha Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. BLOOD, 2020, 136 (1), ⟨10.1182/blood-2020-134602⟩. ⟨hal-03606393⟩